Showing Results for: “diabetes”

Strategic investment backs UpDoc’s clinical AI platform, deploying patient-facing AI agents to transform chronic disease care at scale Today, the American Diabetes Association ® (ADA) announced a strategic investment in UpDoc, an enterprise-ready clinical artificial intelligence (AI) company developing physician-grade agentic AI. The investment from the ADA’s Innovation Fund validates UpDoc’s evidence-based approach to chronic disease management and will accelerate the company’s mission to deliver clinical-grade, agentic AI-powered interventions to millions of people living with diabetes and

The Teplizumab Prevention Trial has given validity to the concept that immune therapy can delay the diagnosis of type 1 diabetes (T1D), according to findings presented at a symposium entitled “New Therapeutic Approaches and Insights for Type 1 Diabetes” today at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions® at the Moscone Convention Center in San Francisco. Family members of someone with T1D have a 15 times greater risk of developing T1D than individuals from the general population. Testing can determine the presence of autoantibodies, indicating risk for T1D, and the

The New England Journal of Medicine: AMPLITUDE O trial reveals regular use of efpeglenatide has potential to improve outcomes for high-risk diabetes patients with heart or kidney disease Data released today from a large-scale, international clinical trial show significant reduction in the first occurrence of a heart attack, stroke, or death, and a reduction in progression of kidney disease in patients with type 2 diabetes with weekly use of efpeglenatide, an injectable drug with glucose- and weight-lowering effects. The findings were presented at the virtual 81st Scientific Sessions of the

Linagliptin, when added to usual diabetes care in people with type 2 diabetes (T2D) with increased risk of cardiovascular (CV) and/or renal disease, resulted in incidences of CV and renal events comparable to placebo over a median period of 2.2 years across a broad range of age and kidney function status, according to a symposium presentation today titled “Linagliptin Trial in Type 2 Diabetes Mellitus at High Cardiovascular Risk with Chronic Kidney Disease,” at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions® at the Moscone Convention Center in San Francisco

Let’s keep speaking up on behalf of the 155 million individuals living with diabetes and prediabetes. Your voices and advocacy matter. And we are stronger together.

There are currently more than 37 million American adults living with diabetes. Almost three times that many adults (96 million) are living with prediabetes and 90% are completely unaware. Anyone with diabetes is at risk for diabetes-related eye diseases such as diabetic retinopathy, macular edema, glaucoma, and cataracts. Some groups, however, are at a higher risk of losing their vision or going blind from diabetes, including Black Americans, Hispanics and Latinos, American Indians, and Alaska Natives. While genetic factors likely play a role in these health inequities, so do social, economic

American Diabetes Association Symposium Demonstrates Benefits of Once Weekly Drug for Weight Loss and Glycemic Control Today, findings from SURMOUNT-2, a study of tirzepatide in participants with type 2 diabetes who have obesity were announced, demonstrating more weight loss in individuals with diabetes than any other medication to date. The results were presented at the 83rd Scientific Sessions of the American Diabetes Association ® (ADA) in San Diego, CA and were simultaneously published in The Lancet. Obesity impacts 650 million people worldwide including nearly half of all Americans and is

The American Diabetes Association® (ADA) applauds Governor Jeff Landry and the Louisiana legislature for their bipartisan support of Senate Bill 433 (SB 433), landmark legislation expanding Medicaid coverage of obesity medications. Obesity is a chronic, complex disease affecting the health and well-being of Louisianans; it increases the risk of serious complications including type 2 diabetes, cardiovascular disease, and kidney disease. Access to evidence-based treatment remains one of the most significant challenges facing individuals managing chronic conditions. “The ADA is grateful to

Over 34 million American adults currently live with diabetes and an additional 88 million are living with prediabetes, yet 85% of them do not know they have it. People living with diabetes or prediabetes are at an increased risk for developing a diabetes-related eye disease, such as diabetic retinopathy, diabetic macular edema, glaucoma, and cataracts. Even more troubling, recent polls indicate that 1 in 4 people are putting off their annual eye exams due to the COVID-19 pandemic. Fortunately, vision loss from diabetes-related eye disease is 95% preventable with early detection, timely

People living with diabetes are invited to share their story of better living made possible due to insulin The American Diabetes Association ® (ADA), along with the nation’s leading diabetes organizations, unveiled Let’s Talk Insulin today, a campaign commemorating the 100th anniversary of the discovery of insulin. Throughout the year, the ADA and other organizations in the diabetes community will showcase a century of advancements and innovations in insulin therapy, as well as what’s ahead through educational events, support resources, and advocacy for research funding. “The discovery of